The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and main ...
The enzyme replacement therapy (ERT) market is projected to grow significantly, rising from US$ 10,707.6 million in ...
The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, ...
Yemaachi Biotech, a pioneering genomics research company based in Ghana, announced today a partnership with Roche to launch The African Cancer Atlas (TACA). This initiative aims to address the ...
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discu ...
Earlier this month, Sarepta Therapeutics, which is responsible for commercializing Elevidys in the US while Roche markets Elevidys in other countries, reported preliminary financial results and ...
Objective indices of functional capacity in patients with diabetic cardiomyopathy and stage B heart failure (HF) have not been comprehensively defined. We sought to characterize the cardiopulmonary ...
In 2019, Roche entered into a global collaboration agreement with Sarepta Therapeutics, Inc. to commercialise Elevidys in territories outside the US. Study 101 (NCT03375164), a phase I/II study ...
Roche entered into a worldwide partnership with Sarepta Therapeutics in 2019 to commercialise the gene therapy outside of the US. Subjects in the trial received one dose of Elevidys or a placebo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback